Company profile
AGENUS INC
NASDAQ:AGENBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BALSTILIMAB | phase3 | — | 11 | active |
| VITESPEN | phase3 | — | 3 | completed, terminated |
| QUILLAJA SAPONIN (QS-21) | phase2 | — | 5 | completed, terminated |
| ZALIFRELIMAB | phase2 | — | 6 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05033132 | phase2 | withdrawn | 2021-10-01 | 2024-12-30 | Agenus Inc. | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
| NCT00081809 | phase2 | completed | 2000-03-01 | 2005-06-01 | Agenus Inc. | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma |
| NCT05025085 | phase1 | completed | 2021-10-04 | 2023-07-11 | Agenus Inc. | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors |
| NCT04156100 | phase1 | terminated | 2019-12-10 | 2021-04-08 | Agenus Inc. | A Study in Subjects With Advanced Solid Tumors |
| NCT03104699 | phase1_2 | completed | 2017-04-11 | 2022-06-15 | Agenus Inc. | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer |
FDA applications (0)
No records yet.